Search
Selected Filter
Displaying 131–140 of 508 news results
-
RD Fund Announces New Chair, and Expansion of Board of Directors
In the PressRD Fund Board member and seasoned ophthalmology leader Adrienne Graves, PhD, appointed chair. Ophthalmology luminaries Jean Bennett, MD, PhD, Catherine Bowes Rickman, PhD, and José-Alain Sahel, MD, to join the board.
-
Endogena Launches Clinical Trial of Therapy to Activate Stem Cells in RP Patients’ Retinas
Research NewsThe emerging treatment is gene-agnostic.
-
Kiora to Launch Clinical Trial in Australia for Vision-Restoring Small Molecule for RP Patients
Research NewsThe approach bestows light sensitivity to retinal ganglion cells for people who have lost their photoreceptors
-
Foundation Fighting Blindness Announces Leadership Changes
Foundation NewsJason Menzo named chief executive officer • Russell Kelley, PhD, MBA, appointed managing director of the RD Fund • Ben Yerxa, PhD, to lead Opus Genetics, the first RD Fund- and Foundation-backed spin-off company.
-
Research News
The newly approved drug reduces the pathologic hunger associated with BBS
-
In the Press
Funds to support advancement of two clinical trials through proof of concept: NPI-001 for retinitis pigmentosa in Usher syndrome and NPI-002 to slow cataract progression.
-
Over Thirty Presentations Highlighted during the 2022 Retinal Cell & Gene Therapy Innovation Summit
Research NewsIn its seventh year, the Retinal Cell & Gene Therapy Innovation Summit featured 34 presentations from industry experts from around the world.
-
Luxa Doses First Participant in Clinical Trial of RPE Stem Cells for Dry AMD Patients
Research NewsThe company’s RPESC-RPE cell product is composed of progenitor-stage RPE cells grown from human eyes donated to eye banks.
-
ProQR’s Sepofarsen Improves Vision Significantly for Girl with LCA10
Research NewsHowever, the Phase 2/3 Illuminate trial for sepofarsen didn’t meet its endpoints at 12 months
-
AGTC’s XLRP Gene Therapy Performs Well in Extension of Phase 2 Clinical Trial
Research NewsThe three-month results support the planned launch of the company’s Phase 2/3 Vista trial
.png)
